Trade Pluri Inc. - PLUR CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.2260 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 4.227 |
| Open | 4.187 |
| 1-Year Change | 680.87% |
| Day's Range | 4.187 - 4.197 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 17, 2025 | 4.1970 | 0.0100 | 0.24% | 4.1870 | 4.1970 | 4.1870 |
| Jan 16, 2025 | 4.2270 | -0.0200 | -0.47% | 4.2470 | 4.2470 | 4.2070 |
| Jan 15, 2025 | 4.2570 | 0.1600 | 3.91% | 4.0970 | 4.2770 | 4.0870 |
| Jan 14, 2025 | 4.0870 | -0.1600 | -3.77% | 4.2470 | 4.2570 | 3.9870 |
| Jan 13, 2025 | 4.1770 | 0.0700 | 1.70% | 4.1070 | 4.1770 | 4.0870 |
| Jan 10, 2025 | 4.1470 | 0.0500 | 1.22% | 4.0970 | 4.1470 | 4.0870 |
| Jan 8, 2025 | 4.1670 | -0.3300 | -7.34% | 4.4970 | 4.5070 | 4.1670 |
| Jan 7, 2025 | 4.1770 | -0.4300 | -9.33% | 4.6070 | 4.6470 | 4.1770 |
| Jan 6, 2025 | 4.4770 | -0.0300 | -0.67% | 4.5070 | 4.5870 | 4.3970 |
| Jan 3, 2025 | 4.2370 | -0.0100 | -0.24% | 4.2470 | 4.4370 | 4.0770 |
| Jan 2, 2025 | 4.3070 | 0.0300 | 0.70% | 4.2770 | 4.3170 | 4.2570 |
| Dec 31, 2024 | 4.1470 | -0.0100 | -0.24% | 4.1570 | 4.2170 | 3.7870 |
| Dec 30, 2024 | 4.1370 | -0.1700 | -3.95% | 4.3070 | 4.3070 | 4.1370 |
| Dec 27, 2024 | 4.2470 | -0.0100 | -0.23% | 4.2570 | 4.4670 | 4.0570 |
| Dec 26, 2024 | 4.3570 | 0.0900 | 2.11% | 4.2670 | 4.6770 | 4.1470 |
| Dec 24, 2024 | 4.0970 | -0.3300 | -7.45% | 4.4270 | 4.4470 | 4.0970 |
| Dec 23, 2024 | 4.3670 | -0.1900 | -4.17% | 4.5570 | 4.5670 | 4.3670 |
| Dec 20, 2024 | 4.4870 | 0.2300 | 5.40% | 4.2570 | 4.7370 | 4.2570 |
| Dec 19, 2024 | 4.3570 | -0.0300 | -0.68% | 4.3870 | 4.6170 | 4.0470 |
| Dec 18, 2024 | 4.0270 | -0.4200 | -9.44% | 4.4470 | 4.4970 | 4.0270 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Pluri Inc. Company profile
About Pluristem Therapeutics Inc.
Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.
Financial summary
BRIEF: For the six months ended 31 December 2021, Pluristem Therapeutics Inc. revenues was not reported. Net loss increased 6% to $22.4M. Higher net loss reflects General and administrative expenses increase of 30% to $4.8M (expense), Stock-based Compensation in SGA increase of 9% to $4.6M (expense), Research & Development Expense decrease of 75% to $72K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.82 to -$0.70.
Equity composition
Common Stock $0.00001 Par, 01/13, 100M auth., 58,333,206 issd. Insiders control 11.74%. IPO: NA. 11/07,1-for-200 reverse stock split. 11/07, Name changed from Pluristem Life Systems, Inc. 12/07, Exchanged changed from OTC Bulletin Board to NASDAQ.
| Industry: | Biotechnology & Medical Research (NEC) |
Matam Park Building 5
HAIFA
3508409
IL
News
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com